Table 1.
Compliance results by therapeutic class, study design and data source
| Therapeutic class (%) | Study design (%) | Data source (%) | ||||||
|---|---|---|---|---|---|---|---|---|
| Measure | AHTs (n = 53) | OADs (n = 35) | LLTs (n = 32) | Total* (n = 139) | Prospective (n = 65) | Retrospective (n = 54) | MEMS (n = 21) | Pharmacy claims (n = 73) |
| Average 12-month MPR | 67 (12) | 76 (10) | 74 (8) | 72 (34) | 79 (5) | 71 (29) | 75 (4) | 71 (29) |
| Proportion of patients withMPR > 80% at 12 months | 64 (7) | 58 (7) | 51 (9) | 59 (28) | 67 (6) | 57 (22) | 65 (3) | 57 (23) |
Number of studies (n) are shown in parentheses.
*
Includes studies with multiple treatment arms. AHTs, antihypertensives; LLTs, lipid-lowering therapies; MEMS, medication event monitoring system; MPR, medication possession ratio; OADs, oral antidiabetics.